Supplemental material
Journal of Medical Economics
Volume 26, 2023 - Issue 1
Oncology
Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis
Mikin V. Patela Section of Interventional Radiology, Department of Radiology, University of Chicago Medicine, Chicago, IL, USA
https://orcid.org/0000-0001-8715-2063
https://orcid.org/0000-0001-8715-2063, Heather Daviesb York Health Economics Consortium, University of York, Heslington, UKhttps://orcid.org/0000-0003-1943-3765
https://orcid.org/0000-0003-1943-3765, Abimbola O. Williamsc Boston Scientific, Marlborough, MA, USAhttps://orcid.org/0000-0003-1982-8417
https://orcid.org/0000-0003-1982-8417, Tom Bromilowb York Health Economics Consortium, University of York, Heslington, UKhttps://orcid.org/0000-0003-2494-5685
https://orcid.org/0000-0003-2494-5685, , Stuart Mealingb York Health Economics Consortium, University of York, Heslington, UKCorrespondence[email protected]
https://orcid.org/0000-0002-2564-1440
https://orcid.org/0000-0002-2564-1440, Hayden Holmesb York Health Economics Consortium, University of York, Heslington, UKhttps://orcid.org/0000-0003-2559-061X
https://orcid.org/0000-0003-2559-061X, & show all